Markets:

Overview

News

Currencies

International

Treasuries

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

2.110 -0.060 (-2.76%)

Streaming Delayed Price Updated: 11:07 AM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

38 39 Next >

Cassava Sciences Stock Rises On Interim Safety Review Of Simufilam Phase 3 Trials ↗

September 24, 2024

Cassava Sciences, Inc. (NASDAQ: SAVA) shares trading higher following the announcement of a positive interim safety review of its Alzheimer's drug candidate, simufilam. Here's what you need to know.

Via Benzinga

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

September 24, 2024

From Cassava Sciences, Inc.

Via GlobeNewswire

Cassava Sciences Names Rick Barry as Chief Executive Officer

September 09, 2024

Claude Nicaise, M.D. appointed Chairman of the Board

From Cassava Sciences, Inc.

Via GlobeNewswire

Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference

September 03, 2024

From Cassava Sciences, Inc.

Via GlobeNewswire

Here's How Much $100 Invested In Cassava Sciences 5 Years Ago Would Be Worth Today ↗

August 07, 2024

Via Benzinga

Market Whales and Their Recent Bets on SAVA Options ↗

August 06, 2024

Via Benzinga

9 Health Care Stocks Whale Activity In Today's Session ↗

August 13, 2024

Via Benzinga

Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?

August 10, 2024

Cassava Sciences has become a hot topic among traders due to its recent surge in volatility, liquidity, and overall market performance.

Via MarketBeat

SAVA Stock Earnings: Cassava Sciences Beats EPS for Q2 2024 ↗

August 08, 2024

SAVA stock results show that Cassava Sciences beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates

August 08, 2024

From Cassava Sciences, Inc.

Via GlobeNewswire

What's Going On With Cassava Sciences Today? ↗

August 05, 2024

Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading higher Monday. Here's what you need to know.

Via Benzinga

(SAVA) - Analyzing Cassava Sciences's Short Interest ↗

August 02, 2024

Via Benzinga

What's Going On With Cassava Sciences Shares Today? ↗

July 31, 2024

Cassava Sciences is set to report its second-quarter earnings on Aug. 13, with an anticipated loss of 40 cents per share, according to Benzinga Pro.

Via Benzinga

Cassava Sciences News: Why Is SAVA Stock Trending Today? ↗

August 06, 2024

Cassava Sciences stock is down on Tuesday even as investors take note of SAVA shares alongside a couple of pieces of news.

Via InvestorPlace

Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson

August 05, 2024

From Cassava Sciences, Inc.

Via GlobeNewswire

Cassava Sciences Shares Are Trading Higher Today: What You Need To Know ↗

August 02, 2024

Cassava Sciences, Inc. (NASDAQ: SAVA) saw its stock price soar by 15.5% to $27.13, an increase of $3.64, amid rising short interest and an anticipated conference call to discuss recent developments.

Via Benzinga

Get Your Money Out of These 3 Healthcare Stocks ASAP ↗

August 02, 2024

Many companies in the healthcare sector have great outlooks but these healthcare stocks to sell are facing very tough challenges

Via InvestorPlace

8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803% ↗

August 01, 2024

Macro environment favors large-caps, but July saw impressive gains for small-caps, with Serve Robotics leading at 803% and Q32 Bio at 101%.

Via Benzinga

Here's How Much $1000 Invested In Cassava Sciences 5 Years Ago Would Be Worth Today ↗

July 23, 2024

Via Benzinga

Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET

August 01, 2024

From Cassava Sciences, Inc.

Via GlobeNewswire

Match Group Posts Upbeat Sales, Joins Modine Manufacturing, Scotts Miracle-Gro, NVIDIA And Other Big Stocks Moving Higher On Wednesday ↗

July 31, 2024

Via Benzinga

SmartRent (SMRT) Stock Plunges 21% as CEO Steps Down ↗

July 30, 2024

SmartRent stock is falling on Tuesday as SMRT investors react to the resignation of the company's CEO and suspension of its 2024 outlook.

Via InvestorPlace

Microsoft Office Outage: Microsoft Investigates Applications, Services Issue ↗

July 30, 2024

A Microsoft Office outage has workers annoyed as its causing problems with them being able to use the company's services.

Via InvestorPlace

SAVA Stock: Cassava Sciences Extends Simufilam Trials as Much as 36 Months ↗

July 30, 2024

Cassava Sciences has announced plans to extend trials for its Alzheimer’s treatment drug. This news isn't helping SAVA stock.

Via InvestorPlace

Cassava Sciences Announces Expansion of Open-Label Extension Trials

July 30, 2024

From Cassava Sciences, Inc.

Via GlobeNewswire

Get Your Money Out of These 3 Biotech Stocks Before the End of July ↗

July 28, 2024

These stocks are at a risk of providing negative returns to shareholders due to the several operational challenges faced by the companies.

Via InvestorPlace

Nasdaq Up Triple Digits Amid Tech Resurgence ↗

July 22, 2024

The Nasdaq Composite Index is up 190 points as Big Tech stages a comeback following last week's selloff.

Via Talk Markets

Topics Stocks

Cassava Sciences Advances Alzheimer's Drug Through High-Stakes Phase 3 Trials ↗

July 22, 2024

Cassava Sciences' Phase 3 trials for Alzheimer's drug simufilam could change treatment standards. With trials costing millions, success could revolutionize care for millions. CEO emphasizes...

Via Benzinga

Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

July 22, 2024

Via Benzinga

Why Is MIRA Pharmaceuticals (MIRA) Stock Up 318% Today? ↗

July 22, 2024

MIRA Pharmaceuticals stock is up on Monday after the company posted results from a pre-clinical trial of its novel oral ketamine analog.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.